Suppr超能文献

肝硬化患者肝微粒体储备减少。以氨基比林作为模型药物的研究。

Decreased hepatic microsomal reserve in patients with cirrhosis. Studies using aminopyrine as model drug.

作者信息

Piken E, Hepner G W

出版信息

J Lab Clin Med. 1979 Dec;94(6):947-54.

PMID:501215
Abstract

It is unclear whether hepatic drug metabolism which is decreased in patients with liver disease, can be stimulated by enzyme-inducing drugs. Hepatic microsomal reserve, defined as the difference between the basal and phenobarbital-stimulated ABT, was therefore studied in eight healthy control subjects and 12 patients with stable alcoholic cirrhosis. The ABT increased significantly (p less than 0.01) from a basal value of 6.1% +/- 0.8 (mean +/- S.D.) to 8.9% +/- 0.8 in the eight control subjects after phenobarbital ingestion. In the 12 patients with alcoholic cirrhosis the basal ABT was 2.9% +/- 1.5 and did not change significantly after phenobarbital ingestion, when the value was 3.0% +/- 1.6. A small increase in the ABT occurred after phenobarbital ingestion in five of the patients with alcoholic cirrhosis, but in no patient did this increase bring the ABT within normal limits. We conclude that in many patients with stable alcoholic cirrhosis aminopyrine metabolism is decreased and cannot be corrected by treatment with phenobarbital.

摘要

尚不清楚肝脏疾病患者体内降低的肝脏药物代谢是否能被酶诱导药物所刺激。因此,对8名健康对照者和12名稳定期酒精性肝硬化患者的肝脏微粒体储备进行了研究,肝脏微粒体储备定义为基础氨基比林清除率(ABT)与苯巴比妥刺激后的ABT之差。8名对照者在摄入苯巴比妥后,ABT从基础值6.1%±0.8(均值±标准差)显著增加(p<0.01)至8.9%±0.8。12名酒精性肝硬化患者的基础ABT为2.9%±1.5,摄入苯巴比妥后无显著变化,此时的值为3.0%±1.6。12名酒精性肝硬化患者中有5名在摄入苯巴比妥后ABT有小幅增加,但无一例患者的这一增加使ABT达到正常范围。我们得出结论,在许多稳定期酒精性肝硬化患者中,氨基比林代谢降低,且不能通过苯巴比妥治疗得到纠正。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验